Skip to search formSkip to main contentSkip to account menu

LC16M8

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Use of the LC16m8 Smallpox Vaccine in Immunocompromised Individuals Is Still Too Risky
We read with some concern the report by Yokote et al. ([1][1]), in which the authors recommend that LC16m8, a replicating… 
2014
2014
Glycosylated and Nonglycosylated Complement Control Protein of the Lister Strain of Vaccinia Virus
ABSTRACT The vaccinia virus complement control protein (VCP) is a secreted viral protein that binds the C3b and C4b complement… 
2009
2009
Clinical and Immunological Response to Attenuated Tissue-Cultured Smallpox Vaccine LC 16 m 8
THE THREAT OF SMALLPOX BIOterrorism has prompted reconsideration of the need for smallpox vaccination. Serious adverse events… 
2008
2008
Post-Exposure Vaccination with a Highly Attenuated Vaccinia Vaccine, LC16m8, for Protection of Nonhuman Primates from Monkeypox
2004
2004
Smallpox vaccine LC16m8 protects against in vivo challenge
  • 2004
  • Corpus ID: 195138274
1989
1989
Stability of recombinant vaccinia virus LC16m0 or LC16m8: preserved laboratory attenuation markers and conserved expression of inserted HBsAg gene.
1985
1985
Gene Structures of Low‐Neurovirulent Vaccinia Virus LC16m0, LC16m8, and Their Lister Original (LO) Strains
Vaccinia viruses LC16m0 and LC16m8 are temperature‐sensitive and low‐neurovirulent variants derived from the Lister (Elstree) (LO… 
1977
1977
Clinical and Immunological Studies on the use of LC16m8 in Primary Smallpox Vaccinations
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)